Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne R Pariser

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|February 26, 2016
Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical holdLarissa Lapteva, Anne R Pariser
Therapeutic Innovation & Regulatory Science|September 18, 2018
Pre-Investigational New Drug Meetings With the FDA: Evaluation of Meeting Content and Characteristics of Applications for New Drug and Biologic ProductsHong H Vu, Anne R Pariser
Journal of General Internal Medicine|July 18, 2014
Important role of translational science in rare disease innovation, discovery, and drug developmentAnne R Pariser, William A Gahl
Orphanet Journal of Rare Diseases|November 8, 2018
From scientific discovery to treatments for rare diseases - the view from the National Center for Advancing Translational Sciences - Office of Rare Diseases ResearchPetra Kaufmann, Anne R Pariser, Christopher Austin
Nature Reviews. Drug Discovery|December 2, 2010
Accelerating orphan drug developmentTimothy R Coté, Kui Xu, Anne R Pariser
Discovery Medicine|April 29, 2011
Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trialsAnne R Pariser, Kui Xu, John Milto, et al.
The Journal of Allergy and Clinical Immunology|August 4, 2012
Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseasesRobert Fiorentino, Gumei Liu, Anne R Pariser, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|January 19, 2012
The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe diseaseEmanuela Lacaná, Lynne P Yao, Anne R Pariser, et al.
Drug Discovery Today|May 9, 2012
Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010Anne R Pariser, Daniel J Slack, Larry J Bauer, et al.
Human Gene Therapy|January 25, 2023
Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy ExperienceRicha Madan Lomash, Oleg Shchelochkov, Randy J Chandler, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|February 26, 2016
Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical holdLarissa Lapteva, Anne R Pariser
Therapeutic Innovation & Regulatory Science|September 18, 2018
Pre-Investigational New Drug Meetings With the FDA: Evaluation of Meeting Content and Characteristics of Applications for New Drug and Biologic ProductsHong H Vu, Anne R Pariser
Journal of General Internal Medicine|July 18, 2014
Important role of translational science in rare disease innovation, discovery, and drug developmentAnne R Pariser, William A Gahl
Orphanet Journal of Rare Diseases|November 8, 2018
From scientific discovery to treatments for rare diseases - the view from the National Center for Advancing Translational Sciences - Office of Rare Diseases ResearchPetra Kaufmann, Anne R Pariser, Christopher Austin
Nature Reviews. Drug Discovery|December 2, 2010
Accelerating orphan drug developmentTimothy R Coté, Kui Xu, Anne R Pariser
Discovery Medicine|April 29, 2011
Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trialsAnne R Pariser, Kui Xu, John Milto, et al.
The Journal of Allergy and Clinical Immunology|August 4, 2012
Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseasesRobert Fiorentino, Gumei Liu, Anne R Pariser, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|January 19, 2012
The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe diseaseEmanuela Lacaná, Lynne P Yao, Anne R Pariser, et al.
Drug Discovery Today|May 9, 2012
Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010Anne R Pariser, Daniel J Slack, Larry J Bauer, et al.
Human Gene Therapy|January 25, 2023
Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy ExperienceRicha Madan Lomash, Oleg Shchelochkov, Randy J Chandler, et al.
Pageof 3